期刊文献+

孕激素与围绝经期情绪障碍相关性的探讨 被引量:1

The Exploration of Relationship between Progestin and Peri-menopausal Emotional Disorder
下载PDF
导出
摘要 目的:探索孕激素在女性围绝经期情绪障碍中的作用。方法:研究对象以抑郁为主伴或不伴焦虑的围绝经期女性57例,及参加体检的、经Zung氏焦虑抑郁自评量表筛选后无抑郁焦虑症状群的围绝经期健康女性 37例,两组年龄范围均介于40-60岁。主要评定工具为HAMD、HAMA、SAS、SDS等量表,并于入院后次晨空腹抽血检测孕激素。结果:HAMD、HAMA评分在女性围绝经期情绪障碍组和健康对照组之间存在着统计学差异(P< 0.01);情绪障碍组的孕激素水平虽然略高于健康对照组,但两者之间差异无统计学意义(P>0.05);情绪障碍组的孕激素与HAMD评分之间没有相关性,而与HAMA评分之间有低度相关性(P<0.05)。结论:孕激素在女性围绝经期情绪障碍的发生、发展中可能发挥着一定的作用。 Objective: To observe the effects of progestin on emotional disorder during peri-menopause in a clinical study. Method: 57 women patients with emotional disorder in Psychiatric Department of the Third Affiliated Hospital of Sun-Yat-Sen University were allocated into the case group, and 37 healthy women without emotional disorder by SDS and SAS screening tests were put into the control group, who were from the Maternal and Child Health Hospital of Haizhu District in Guangzhou City. They were all 40-60 years old. The leading Rating Scales were HAMA, HAMD, SAS, and SDS, and two milliliters of periphery venous blood were obtained for testing progestin level at eight clock in the morning. Result: ①The score of HAMA, HAMD presented some significant difference between the case and control groups. ②There was some statistical difference in progestin between the two groups. ③There was no relationship between progestin and HAMD in the case group, and there was a positive correlation between progestin and HAMA in the case group. Conclusion: Progestin could play a latent role in occurrence and progress of peri-menopausal emotional disorder.
出处 《药物流行病学杂志》 CAS 2005年第5期278-280,共3页 Chinese Journal of Pharmacoepidemiology
关键词 孕激素 围绝经期 情绪障碍 Progestin Peri-menopausal Emotional disorder
  • 相关文献

参考文献8

二级参考文献17

  • 1赵更力,鲍月琴,渠川琰,王向群.更年期妇女抑郁症状的发生情况及其影响因素[J].中华妇产科杂志,1996,31(10):614-616. 被引量:81
  • 2Boukes FS Groeneveld assendelft WJ.Summary or the DCGP practice guiddine"the menopause"[J].Ned Tijdschr Geneeskd,2002,146:1317-1320.
  • 3Siegemann-Danieli N Ron I Kaufman B et al.HRT in breast cancer survivors: ISCADR polipy letter[J].Harefuah,2002,141(11):994-994.
  • 4Writing Group for the WHI Investigatiors. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288: 321-333.
  • 5Mosca L, Collins P, Herington DM, et al. HRT and Cardiovaseular disease. A statement for healtheare professeinals from the AHA. Circulation, 2001,104:499-503.
  • 6ACC/AHA. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-Stmamary article. Circulation ,2003,107:149-158.
  • 7Stephertson J. FDA order estrogen safety warnings. Agency offers guidance for HRT use. JAMA, 2003,289:537-538.
  • 8(HC)Pritehard KI, Khan H, Levine M, et al. Clinical practice guidelines for the care and treatment of breeast cancer: 14. The role of HRT in women with a previous diagnosis of breat cancer. CMAJ, 2002, 166(8): 1017-1022(2002-4).
  • 9NAMS. Amended report from the NAMS Advisory Panel on HRT. Menopause, 2003,10(1) : 6-12.
  • 10NAMS. Role of progestogen in hormone therapy for postmenopausal women: Position statement of NAMS.Menopause, 2003,10(2) : 113.

共引文献86

同被引文献22

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部